Advances in Systemic Lupus Erythematosus Treatment With Monoclonal Antibodies: A Mini-Review.

However, this improvement did not reach statistical significance, indicating that rituximab was not definitively superior to placebo in the primary clinical outcomes.

also in 111,027 other papers